FIELD: medicine.
SUBSTANCE: what is used is a histon deacetylase inhibitor N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide or its pharmaceutically acceptable salt and antimetabolite 5-azacytidine.
EFFECT: method enables suppressing the development or providing the higher clinical effectiveness of myelodysplastic syndrome and acute myeloblastic leucosis.
1 tbl, 2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF HISTONE DEACETYLASE INHIBITORS AND RADIATION | 2006 |
|
RU2436572C2 |
| HYDROXAMATE DERIVATIVES SUITABLE AS DEACETYLASE INHIBITORS | 2001 |
|
RU2302408C2 |
| APPLICATION OF HDAC INHIBITORS FOR TREATING MYELOMA | 2006 |
|
RU2420279C2 |
| OXOAZEPANYLACETAMIDE AND OXOAZEPANYLPHENOXYACETAMIDE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND METHOD FOR INHIBITING HEPATITIS TYPE C VIRUS (HCV) REPLICATION | 2006 |
|
RU2415132C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| SUBSTITUTED DERIVATIVES OF 1-AMINOBUTANE-3-OL, METHOD FOR THEIR PREPARING AND MEDICINAL AGENT | 2001 |
|
RU2288219C2 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
